These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35884561)

  • 1. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.
    Pereira M; Matuszewska K; Glogova A; Petrik J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins as anti-tumor agents: A paradigm for repurposed drugs.
    Tripathi S; Gupta E; Galande S
    Cancer Rep (Hoboken); 2024 May; 7(5):e2078. PubMed ID: 38711272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
    Ishikawa T; Hosaka YZ; Beckwitt C; Wells A; Oltvai ZN; Warita K
    Oncotarget; 2018 Jun; 9(50):29304-29315. PubMed ID: 30034619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
    Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
    Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin as a therapeutic agent in gastroenterological cancer.
    Uemura N; Hayashi H; Baba H
    World J Gastrointest Oncol; 2022 Jan; 14(1):110-123. PubMed ID: 35116106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
    Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
    Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
    Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
    Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
    Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
    Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.
    Guerra B; Recio C; Aranda-Tavío H; Guerra-Rodríguez M; García-Castellano JM; Fernández-Pérez L
    Front Oncol; 2021; 11():626971. PubMed ID: 33718197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
    Pandyra A; Mullen PJ; Kalkat M; Yu R; Pong JT; Li Z; Trudel S; Lang KS; Minden MD; Schimmer AD; Penn LZ
    Cancer Res; 2014 Sep; 74(17):4772-82. PubMed ID: 24994712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The UPR
    Oks O; Lewin S; Goncalves IL; Sapir A
    Genetics; 2018 Jun; 209(2):457-473. PubMed ID: 29599115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins.
    Buchou C; Laud-Duval K; van der Ent W; Grossetête S; Zaidi S; Gentric G; Corbé M; Müller K; Del Nery E; Surdez D; Delattre O
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
    Tutuska K; Parrilla-Monge L; Di Cesare E; Nemajerova A; Moll UM
    Cell Death Dis; 2020 Apr; 11(4):274. PubMed ID: 32332697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.
    Iannelli F; Lombardi R; Milone MR; Pucci B; De Rienzo S; Budillon A; Bruzzese F
    Recent Pat Anticancer Drug Discov; 2018; 13(2):184-200. PubMed ID: 29189178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
    Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins: a repurposed drug to fight cancer.
    Jiang W; Hu JW; He XR; Jin WL; He XY
    J Exp Clin Cancer Res; 2021 Jul; 40(1):241. PubMed ID: 34303383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins.
    Ji L; Liu C; Yuan Y; Gao H; Tang ZX; Yang Z; Liu ZT; Jiang GH
    Fundam Clin Pharmacol; 2020 Feb; 34(1):4-10. PubMed ID: 31241783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins as Anticancer Agents in the Era of Precision Medicine.
    Longo J; van Leeuwen JE; Elbaz M; Branchard E; Penn LZ
    Clin Cancer Res; 2020 Nov; 26(22):5791-5800. PubMed ID: 32887721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
    Qi XF; Zheng L; Lee KJ; Kim DH; Kim CS; Cai DQ; Wu Z; Qin JW; Yu YH; Kim SK
    Cell Death Dis; 2013 Feb; 4(2):e518. PubMed ID: 23449454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.